These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9222274)

  • 21. The evolution and origin of motor complications in Parkinson's disease.
    Obeso JA; Rodriguez-Oroz MC; Chana P; Lera G; Rodriguez M; Olanow CW
    Neurology; 2000; 55(11 Suppl 4):S13-20; discussion S21-3. PubMed ID: 11147505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parkinson's disease: diagnosis and treatment.
    Rao SS; Hofmann LA; Shakil A
    Am Fam Physician; 2006 Dec; 74(12):2046-54. PubMed ID: 17186710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of Parkinson's disease a review of current and new therapies.
    Mendis T; Suchowersky O; Lang A; Gauthier S
    Can J Neurol Sci; 1999 May; 26(2):89-103. PubMed ID: 10352867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Neuropsychiatric disorders in Parkinson's disease].
    Noé-Sebastián E; Irimia-Sieira P; Pomares-Arias E; Martínez-Vila E; Luquin-Piudo MR
    Rev Neurol; 2001 Apr 1-15; 32(7):676-81. PubMed ID: 11391498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repetitive speech phenomena in Parkinson's disease.
    Benke T; Hohenstein C; Poewe W; Butterworth B
    J Neurol Neurosurg Psychiatry; 2000 Sep; 69(3):319-24. PubMed ID: 10945806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuropsychiatric Symptoms in Parkinson's Disease.
    Aarsland D; Kramberger MG
    J Parkinsons Dis; 2015; 5(3):659-67. PubMed ID: 26406147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
    Reichmann H; Emre M
    Expert Rev Neurother; 2012 Feb; 12(2):119-31. PubMed ID: 22288667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Neuropsychiatric manifestations in Parkinson's disease].
    Oikonomou E; Paparrigopoulos T
    Psychiatriki; 2015; 26(2):116-30. PubMed ID: 26197101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levodopa induced motor complications in Thai Parkinson's disease patients.
    Kulkantrakorn K; Tiamkao S; Pongchaiyakul C; Pulkes T
    J Med Assoc Thai; 2006 May; 89(5):632-7. PubMed ID: 16756048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias.
    Hauser RA
    Geriatrics; 2006 Sep; 61(9):14-20. PubMed ID: 16989543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis and Management of Parkinson's Disease.
    Tarakad A; Jankovic J
    Semin Neurol; 2017 Apr; 37(2):118-126. PubMed ID: 28511252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. When time is of the essence: Managing care in emergency situations in Parkinson's disease.
    Prasad S; Pal PK
    Parkinsonism Relat Disord; 2019 Feb; 59():49-56. PubMed ID: 30253924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of motor fluctuations in Parkinson's disease: recent developments and future directions.
    Ramirez-Zamora A; Molho E
    Expert Rev Neurother; 2014 Jan; 14(1):93-103. PubMed ID: 24328720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cognitive and neuropsychiatric disorders in Parkinson's disease].
    Rodríguez-Constenla I; Cabo-López I; Bellas-Lamas P; Cebrián E
    Rev Neurol; 2010 Feb; 50 Suppl 2():S33-9. PubMed ID: 20205140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
    Koller W; Guarnieri M; Hubble J; Rabinowicz AL; Silver D
    J Neural Transm (Vienna); 2005 Feb; 112(2):221-30. PubMed ID: 15503197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Motor complications in Parkinson's disease.
    Ondo WG
    Int J Neurosci; 2011; 121 Suppl 2():37-44. PubMed ID: 22035028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Psychic disorders].
    Pollak P
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S125-31. PubMed ID: 12690672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.
    Lhommée E; Klinger H; Thobois S; Schmitt E; Ardouin C; Bichon A; Kistner A; Fraix V; Xie J; Aya Kombo M; Chabardès S; Seigneuret E; Benabid AL; Mertens P; Polo G; Carnicella S; Quesada JL; Bosson JL; Broussolle E; Pollak P; Krack P
    Brain; 2012 May; 135(Pt 5):1463-77. PubMed ID: 22508959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial.
    Lhommée E; Wojtecki L; Czernecki V; Witt K; Maier F; Tonder L; Timmermann L; Hälbig TD; Pineau F; Durif F; Witjas T; Pinsker M; Mehdorn M; Sixel-Döring F; Kupsch A; Krüger R; Elben S; Chabardès S; Thobois S; Brefel-Courbon C; Ory-Magne F; Regis JM; Maltête D; Sauvaget A; Rau J; Schnitzler A; Schüpbach M; Schade-Brittinger C; Deuschl G; Houeto JL; Krack P;
    Lancet Neurol; 2018 Mar; 17(3):223-231. PubMed ID: 29452685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.